Director at AEON Biopharma (AEON) granted 222,684 RSUs

Rhea-AI Filing Summary

Forth Marc reported acquisition or exercise transactions in this Form 4 filing.

AEON Biopharma director Marc Forth reported an equity award of 222,684 shares of Class A Common Stock in the form of restricted stock units (RSUs). The RSUs were granted on June 17, 2026 at no cash price and represent compensation rather than an open-market purchase.

The RSUs vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the date of the company’s 2027 annual meeting of stockholders, subject to his continued service. Following this award, Forth directly holds 973,231 shares of AEON Biopharma common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Forth Marc

Role null

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	222,684	$0.00	--

Holdings After Transaction: Class A Common Stock — 973,231 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 222,684 shares Grant price per RSU: $0.0000 per share Total shares after transaction: 973,231 shares +2 more

5 metrics

RSU grant size 222,684 shares Restricted stock units granted on June 17, 2026

Grant price per RSU $0.0000 per share Equity compensation award, not open-market purchase

Total shares after transaction 973,231 shares Direct holdings following RSU award

Vesting period 1 year Earlier of one-year from Grant Date or 2027 annual meeting

Grant Date June 17, 2026 Date RSUs were awarded to Marc Forth

Key Terms

restricted stock units ("RSUs"), Grant Date, annual meeting of the Company's stockholders

3 terms

restricted stock units ("RSUs") financial

"Represents an award of restricted stock units ("RSUs") granted on June 17, 2026"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Grant Date financial

"granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

annual meeting of the Company's stockholders financial

"the date of the 2027 annual meeting of the Company's stockholders, subject to continued service"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 06:20 PM Accepted by SEC EDGAR 06/22/2026 - 06:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Forth Marc

(Last) (First) (Middle)

C/O AEON BIOPHARMA, INC.

5 PARK PLAZA, SUITE 1750

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AEON Biopharma, Inc. [ AEON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock(1)	06/17/2026		A		222,684	A	$0(1)	973,231	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

	/s/ Alexander Wilson, as Attorney-in-Fact, for Marc Forth	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AEON Biopharma (AEON) report for Marc Forth?

AEON Biopharma reported that director Marc Forth received an award of 222,684 restricted stock units (RSUs) of Class A Common Stock. This equity grant is compensation and not an open-market share purchase, and it increases his direct holdings reported on the Form 4.

When were Marc Forth’s 222,684 AEON Biopharma RSUs granted?

The 222,684 restricted stock units granted to director Marc Forth were awarded on June 17, 2026, defined as the Grant Date. This date starts the vesting timeline used to determine when the RSUs convert into shares of AEON Biopharma Class A Common Stock.

What is the vesting schedule for Marc Forth’s AEON Biopharma RSU grant?

Marc Forth’s RSUs vest in full on the earlier of one year after the June 17, 2026 Grant Date or the date of AEON Biopharma’s 2027 annual meeting of stockholders. Vesting remains conditional on his continued service through the applicable vesting date specified.

Did Marc Forth pay cash for the 222,684 AEON Biopharma RSUs?

No, the 222,684 RSUs were granted at a price of $0.0000 per unit, indicating a compensation award rather than a cash purchase. Such grants typically reflect equity-based remuneration for board or executive service at AEON Biopharma.

How many AEON Biopharma shares does Marc Forth hold after this RSU award?

After the RSU award reported in the Form 4, Marc Forth is shown holding 973,231 shares of AEON Biopharma Class A Common Stock directly. This total reflects his ownership following the 222,684 restricted stock units grant disclosed in the filing.

Is Marc Forth’s AEON Biopharma RSU grant an open-market insider purchase or sale?

The transaction is classified as a grant or award acquisition (code A), not an open-market buy or sell. The RSUs were issued at no cash price as part of equity compensation, so they do not represent a discretionary market trade in AEON Biopharma shares.